atrc-101
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04244552)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Squamous Cell Carcinoma · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Melanoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04244552 | Phase 1 | Feb 29, 2020 | Atreca, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atreca, Inc. | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1